0001601830-25-000035 Sample Contracts
SALES AGREEMENTSales Agreement • February 28th, 2025 • Recursion Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
Recursion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Citigroup Global Markets Inc., as sales agent and/or principal (the “Agent”), shares of the Company’s Class A common stock, par value $0.00001 per share (the “Class A Common Shares”), having an aggregate offering price of up to $500,000,000 on the terms set forth in this sales agreement (this “Agreement”). The Class A Common Shares and the shares of the Company’s Class B common stock, par value $0.00001 per share, are referred to herein as the “Common Stock.”
Global Access Commitments AgreementGlobal Access Commitments Agreement • February 28th, 2025 • Recursion Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
This Global Access Commitments Agreement (including all appendices, exhibits and attachments hereto, the “Agreement”) is entered into as of September 1, 2021 (“Effective Date”), by and among the Bill & Melinda Gates Foundation, a Washington charitable trust that is a tax-exempt private foundation (the “Foundation”), Exscientia Limited (registered number 13483814), a private limited company incorporated in England and Wales (the “Company”) and Exscientia AI Limited, (registered number SC428761), a private limited company incorporated under the laws of Scotland that is a wholly-owned subsidiary of the Company (“Exscientia”), in connection with the investment by the Foundation of Thirty-Five Million dollars (US$35,000,000) (the “Foundation Investment”) in American Depositary Shares of the Company. The Foundation is making the Foundation Investment to induce the Company and Exscientia to perform the Global Access Commitments set forth herein, and the Company and Exscientia acknowledge and
RESEARCH COLLABORATION AGREEMENT dated September 19, 2023 by and between EXSCIENTIA AI LTD. and MERCK HEALTHCARE KGAAResearch Collaboration Agreement • February 28th, 2025 • Recursion Pharmaceuticals, Inc. • Biological products, (no disgnostic substances)
Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.
TRANSITION AGREEMENT AND RELEASETransition Agreement and Release • February 28th, 2025 • Recursion Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Utah
This Transition Agreement and Release (“Agreement”) is made by and between Tina Marriott (“Employee”) and Recursion Pharmaceuticals, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”).
ContractResearch Collaboration and License Option Agreement • February 28th, 2025 • Recursion Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • London
Certain information in this document, marked by brackets [****], has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed.
SEPARATION AGREEMENT AND RELEASESeparation Agreement • February 28th, 2025 • Recursion Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Utah
This Separation Agreement and Release (“Agreement”) is made by and between Michael Secora (“Employee”) and Recursion Pharmaceuticals, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”).